Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002290 · ClinicalTrials.gov registry record · NA
The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection
A NA study of HIV Infections, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
- 14
- Study locations
NCT00002290: Completed NA study of HIV Infections, sponsored by Glaxo Wellcome.
NCT00002290 is a NA study of HIV Infections that has completed, run by Glaxo Wellcome. The trial reports 14 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002290, a NA study of HIV Infections, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
- 14
- Study locations
Study Summary
This double-blind, placebo-controlled study is designed to determine the long-term safety and efficacy of concurrent oral Retrovir / Zovirax (AZT and ACV) therapy and oral AZT therapy alone, in the treatment of early symptomatic HIV infection. Efficacy will be evaluated by monitoring the incidence, severity, and time of development of opportunistic infections and other manifestations of advanced symptomatic HIV infection. The effects of the combination and single AZT therapy on immune function and viral replication will also be evaluated. Study participants will be monitored for evidence of toxicity or intolerance to concurrent AZT / ACV administration and AZT therapy alone.
Conditions Studied
Interventions
- DRUG Zidovudine
- DRUG Acyclovir
Study Locations (14)
Texas
- Univ TX Galveston Med Branch - Galveston
- Baylor College of Medicine - Houston
Virginia
- Univ of Virginia Health Sciences Ctr - Charlottesville
- Richmond AIDS Consortium - Richmond
Alabama
- Birmingham Veterans Administration Med Ctr / Univ of Alabama - Birmingham
Arizona
- Univ of Arizona / Health Science Ctr - Tucson
California
- ViRx Inc - San Francisco
District of Columbia
- Georgetown Univ Med Ctr / Main Hosp 4 - Washington D.C.
Florida
- Veterans Administration Med Ctr - Bay Pines
Illinois
- Rush Presbyterian - Saint Luke's Med Ctr - Chicago
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002290 record still lists
NCT00002290 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Zidovudine is the first listed.
NCT00002290 lists 14 locations in 12 states (Texas, Virginia, Alabama).
Frequently Asked Questions
What is clinical trial NCT00002290 about?
NCT00002290 is a clinical study titled "The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection". This double-blind, placebo-controlled study is designed to determine the long-term safety and efficacy of concurrent oral Retrovir / Zovirax (AZT and ACV) therapy and oral AZT therapy alone, in the treatment of early symptomatic HIV infection. Efficacy will be evaluated by monitoring the incidence, ...
What is the current status of trial NCT00002290?
This trial is currently completed. It is a NA study.
What conditions does trial NCT00002290 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002290?
The interventions under investigation include: Zidovudine (DRUG), Acyclovir (DRUG).
Who is sponsoring clinical trial NCT00002290?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002290 being conducted?
This trial has 14 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA